about
Using magnetic resonance imaging to evaluate dendritic cell-based vaccinationThe VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivoExploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccinesSide population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme.MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity.Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo.Poly Ethoxy Ethyl Glycinamide (PEE-G) Dendrimers: Dendrimers Specifically Designed for Pharmaceutical Applications.Strongly magnetic iron nanoparticles improve the diagnosis of small tumours in the reticuloendothelial system by magnetic resonance imaging.Dendritic cells: a journey from laboratory to clinic.Expression of CD1a and Type-1 Polarization Are Dissociated in Human Monocyte-Derived Dendritic CellsCpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens.Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy.Synthesis and Activity of 6″-Deoxy-6″-thio-α-GalCer and Peptide Conjugates.NKT cell-dependent glycolipid-peptide vaccines with potent anti-tumour activity.Activated NKT Cells Can Condition Different Splenic Dendritic Cell Subsets To Respond More Effectively to TLR Engagement and Enhance Cross-Priming.A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy.An autologous leukemia cell vaccine prevents murine acute leukemia relapse after cytarabine treatment.Novel synthesis of alpha-galactosyl-ceramides and confirmation of their powerful NKT cell agonist activity.Splenic Dendritic Cells Involved in Cross-Tolerance of Tumor Antigens Can Play a Stimulatory Role in Adoptive T-Cell Therapy.Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination.Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses.Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens.Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells.Targeting antigen to MHC class II molecules promotes efficient cross-presentation and enhances immunotherapy.5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy.Immature murine NKT cells pass through a stage of developmentally programmed innate IL-4 secretion.B-Lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8(+) T-cells.NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.High avidity antigen-specific CTL identified by CD8-independent tetramer staining.Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy.Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines.An adjuvanted whole cell vaccine as post-remission immunotherapy for acute leukemia.Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help.Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic Cells.Batf3-independent langerin- CX3CR1- CD8α+ splenic DCs represent a precursor for classical cross-presenting CD8α+ DCs.Dendritic cells treated with lipopolysaccharide up-regulate serine protease inhibitor 6 and remain sensitive to killing by cytotoxic T lymphocytes in vivo.Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge.The control of CD8+ T cell responses is preserved in perforin-deficient mice and released by depletion of CD4+CD25+ regulatory T cells.
P50
Q27316977-99CF23AB-A743-4625-8835-4CE2815AB6FFQ28243922-0113124D-5057-4D05-88BD-5FD3B00BC823Q28741462-8BE67768-FB36-4B6E-BE3C-711EF23DB78CQ33852195-22E16104-6986-4637-938F-B70D55F7194CQ34146882-098933E3-C34C-47DD-A00F-D1E6DE2D14C6Q34248293-FE1E2C1E-5963-485B-9064-668898D38644Q34533387-E1A94F0E-866E-42DC-BEF9-873C3B5A0FA0Q34598987-65F72E82-5919-49B0-B29D-874B1C5154E1Q35618115-6429609B-A43E-417A-BF28-C4AC9976C24EQ35804487-2F4EC683-533F-4F43-9AE7-B645F223456AQ36399276-A7A462DA-A760-478F-8727-FE6D87CDE170Q36862410-CC1CEF0B-C413-4C00-89AE-1508DDC5C12FQ38411114-1AD504EC-D001-4F49-9B70-915C1698CEBBQ38412832-B1984D18-21B8-4584-B0E9-C708D219A8A2Q38414216-7781C833-BA94-4115-BB44-6C9F0ABAFE57Q38418416-18C8A2BA-9770-4BC7-9698-648BECA733B7Q38418658-E93178CB-BD91-45B4-82E0-73AC9E78CEE9Q38465959-C9579CB8-A93A-461A-A75D-1E1105C1A07AQ38839106-8059344F-A3E6-4CDE-BE52-D720D4DA4B53Q38943301-E8CBE09C-5E27-46D6-96D3-91064CAA14C4Q39049093-13F85C3E-1CEE-449D-96A0-C669F68EFC1FQ39245543-25977C21-5939-4D1B-A460-4D1503222332Q39386585-C67FD028-106E-4858-8668-C0D79A033B88Q39773095-3D42768C-442D-4B60-BFC2-D64A167B7683Q39843059-3168C6A4-518F-4047-A05B-EC6AB58D0FCAQ39893146-75F94F4A-55B5-47F5-B809-29B3DF47DB6AQ40256708-A6F0AFCC-00EA-43A3-8868-738E7E5F3B83Q40478591-AA800B56-7C58-4FBE-9CC8-20D744BEC12DQ40483578-C7169B89-B15B-4007-8572-CE5EE58AE3D5Q40618321-38DAFF56-AEA3-4EA2-B055-7340BD49803FQ40618338-730CEBD5-8183-418E-A8CA-EA7AC73997FBQ40618967-C1A6B2DA-89A5-4EAA-9FE1-8B0FB8316463Q40725497-36D31D8F-450C-41EB-A6F8-1F80FEBED9B2Q41593302-0F9445F2-4119-4E97-A2E9-DE3AF1871A73Q41827708-5558DB08-4E35-434F-82B7-AE6ACFD41BFFQ42270075-D7842265-EFD3-4E25-8149-A6B5BC39C85EQ42464754-6D71BFE9-B662-48E7-81B3-C52A49BCF458Q42805624-356B95B0-9612-43FA-9E47-ECC1028B7A62Q44807681-9211F91F-C5DF-4182-B1D9-D188D55730DDQ45370941-55819BDC-C720-4F5E-8DF4-2B84B91B47B5
P50
description
researcher ORCID ID = 0000-0002-7584-887X
@en
wetenschapper
@nl
name
Ian F Hermans
@ast
Ian F Hermans
@en
Ian F Hermans
@es
Ian F Hermans
@nl
type
label
Ian F Hermans
@ast
Ian F Hermans
@en
Ian F Hermans
@es
Ian F Hermans
@nl
prefLabel
Ian F Hermans
@ast
Ian F Hermans
@en
Ian F Hermans
@es
Ian F Hermans
@nl
P106
P1153
7003641986
P21
P31
P496
0000-0002-7584-887X